Arbutus Biopharma
ABUS
ABUS
72 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.6% less ownership
Funds ownership: 43.56% → 42.96% (-0.6%)
7% less capital invested
Capital invested by funds: $92.6M → $86.5M (-$6.09M)
Holders
72
Holding in Top 10
–
Calls
$891K
Puts
$472K
Top Buyers
| 1 | +$4.2M | |
| 2 | +$2.74M | |
| 3 | +$477K | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$106K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$96.8K |
Top Sellers
| 1 | -$3.97M | |
| 2 | -$2.78M | |
| 3 | -$428K | |
| 4 |
BlackRock
New York
|
-$403K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$336K |